紧凑型一体化质量光度计，助力研究人员在进行冷冻电镜、原生质谱、生物层干涉、表面等离子共振及其他高成本实验前验证样品质量英国牛津, March 18, 2026 (GLOBE NEWSWIRE) -- 开拓性质量光度计技术开发商 Refeyn 宣布推出 MyMass™ 质量光度计 (MyMassMP)。这款紧凑型仪器旨在回答一个关键的研究问题：样品是否足以进行进一步分析？ 基于结构的药物设计和 AI 驱动的治疗开发正在改变新药的发现方式，但这依赖于高质量的样品。 诸如冷冻电镜、原生质谱 (MS)、生物层干涉 (BLI) 和表面等离子体共振 (SPR) 等结构和生物物理工作流程既耗时又昂贵，而样品质量差仍是这些实验失败的主要原因之一。 在进行资源密集型实验之前，MyMassMP 能快速、准确地评估溶液中样品的纯度、均质性和寡聚化状态。 MyMassMP 基于与 Refeyn TwoMP 质量光度计相同且久经考验的技术打造，后者已受到全球领先的结构生物学和生物治疗实验室的信赖。MyMassMP 将这种质量检查能力集成到一台更简单、独立紧凑的台式仪器。 它配备了用于机载数据分析的集成显示屏和计算机以及专用耗材，可提供 ...

Core Insights - Kaishikedi has recently completed a new financing round of nearly 500 million yuan, led by Zhongping Capital, with participation from multiple investment institutions including Guoshou Capital and QDGC [2][3] - Over the past 10 months, Kaishikedi has raised a total of nearly 1 billion yuan [3] Company Overview - Established in 2017, Kaishikedi is a clinical-stage biotechnology company focused on diseases related to bile acid metabolism disorders [3] - The company is developing innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs), initially focusing on primary biliary cholangitis (PBC) and expanding into metabolic diseases such as metabolic-associated fatty liver disease (MASH), obesity, and diabetes [3] Use of Funds - The recent financing will primarily be used to accelerate the global multi-center Phase III clinical trials for its lead pipeline, targeting global registration for MASH, PBC, and obesity [3] - Additionally, the funds will support the expansion of the research pipeline to develop a series of potential best-in-class/first-in-class therapies in the metabolic disease field [3] Clinical Progress - Kaishikedi's core product CS0159 has received breakthrough therapy designation and orphan drug status from the FDA, achieving significant progress in clinical trials [3] - The oral formulation has successfully completed Phase II trials for MASH in the U.S., and the Phase II core study for PBC has concluded, with Phase III trials currently underway [3] - The research team is also exploring combination therapy with CS0159 and GLP-1 receptor agonists, aiming to enhance weight management and improve liver fat degeneration and inflammation [3] Leadership Statement - Dr. Xu Huaqiang, the founder of Kaishikedi, expressed optimism about accelerating the clinical development and commercialization of CS0159 with the support of both new and existing shareholders, emphasizing the company's commitment to innovative therapies for metabolic diseases [4]